Welcome to ALECENSA®▼(alectinib) on Roche resources

ALECENSA as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).1

ALECENSA as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.1

 

How can your patients with ALK+ advanced NSCLC benefit from treatment with ALECENSA?

ALECENSA, first-line treatment for ALK+ advanced NSCLC patients with or without CNS metastases:

At the December 2017 follow-up of the ALEX study, median PFS was 34.8 months for ALECENSA and 10.9 months for crizotinib2

  • ALECENSA (n=152) delivered median PFS* of 34.8 months (95% Cl: 17.7, NE, Hazard Ratio 0.47 (95% CI:0.34, 0.65) P<0.001) vs 10.9 (95% Cl: 9.1, 12.9) months for crizotinib (n=151)2  
  • Median duration of follow-up was 27.8 months (14.05–31.05) with ALECENSA and 22.8 months (9.23–29.37) with crizotinib (Based on exploratory analysis of the 1st December 2017 data cut off, for the first-line treatment of patients with ALK+ advanced NSCLC)2

*investigator assessed PFS  

Testing how to add into ▼ a paragraph

Dr Brian Clark,
The Beatson West of Scotland Cancer Centre, Glasgow.

In this clip Dr Clark talks about the aims of the ALEX trial.

Dr Andreas Polychronis,
Mount Vernon Cancer Centre, London.

In this video Dr Polychronis discusses the aims and key findings of the ALEX trial.

In a comparative study against crizotinib in ALK positive patients with NSCLC, the cumulative incidence of CNS progression was consistently lower for ALECENSA (12% vs 45%, respectively, HR 0.16: 95% Cl: 0.10, 0.28; P<0.001).3

For more information on the ALEX trial please click on the ALEX Trial page.

Dr Brian Clark,
The Beatson West of Scotland Cancer Centre, Glasgow.

In this video Dr Clark discusses the CNS findings from the ALEX trial.

ALECENSA was generally well tolerated.3

  • The most common adverse events inlcuded constipation (35%), oedema (30%), and myalgia (28%)1
  • The proportion of patients with Grade 3–5 adverse events was lower with alectinib (45%) than with crizotinib (51%)2

For more information on the safety profile of ALECENSA please click on the Safety Information page.

Dr Brian Clark,
The Beatson West of Scotland Cancer Centre, Glasgow.

In this video Dr Clark discusses the secondary endpoints of the ALEX trial.

Dr Andreas Polychronis,
Mount Vernon Cancer Centre, London.

In this video Dr Polychronis reviews the safety findings of the  ALEX trial.

References:

  1. ALECENSA 150 mg hard capsules. Summary of Product Characteristics. Available at: www.medicines.org.uk/emc.
  2. Camidge DR, et al. Poster 9043. Accepted and Presented at: Annual Meeting of ASCO, Chicago, 2018.
  3. Peters S, et al. N Eng J Med. 2017; 377(9): 829–838.

RXUKALEC00072(1)

Date of preparation: August 2019